Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC Birch vs Staloral Birch in Birch Pollen Allergy
NCT00932607Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Jul 2009
- Primary completion
- Feb 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Sublivac Birch in allergic rhinoconjunctivitis (ARC), birch pollen allergy, sponsored by HAL Allergy Group. Started Jul 2009; status: completed.
02
Drugs
Sublivac Birch
03
Conditions
allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on NCT00932607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932607.